Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4092-4097

  Queenan, Anne Marie ^a   Shang, Wenchi ^a   Bush, Karen ^a,b   Flamm, Robert K ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL RNA; BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE;

ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIUM MUTANT; ENZYME ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; UPREGULATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA;

EID: 77957335538     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00060-10     Document Type: Article

References (32)

1. Baum, E. Z., S. M. Crespo-Carbone, B. J. Morrow, T. A. Davies, B. D. Foleno, W. He, A. M. Queenan, and K. Bush. 2009. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:2785-2790.
2. Bonomo, R. A., and D. Szabo. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2):S49-S56.
3. Bush, K., and S. B. Singer. 1989. Effective cooling allows sonication to be used for liberation of β-lactamases from gram negative bacteria. J. Antimicrob. Chemother. 24:82-84.
4. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. CLSI, Wayne, PA.
5. De Champs, C., L. Poirel, R. Bonnet, D. Sirot, C. Chanal, J. Sirot, and P. Nordmann. 2002. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob. Agents Chemother. 46:3031-3034.
6. Dumas, J.-L., C. van Delden, K. Perron, and T. Kohler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.
7. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2008. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn. Microbiol. Infect. Dis. 61:86-95.
8. Henrichfreise, B., I. Wiegand, W. Pfister, and B. Wiedemann. 2007. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 51:4062-4070.
9. Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plesiat. 2006. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351.
10. Hocquet, D., M. Roussel-Delvallez, J.-D. Cavallo, and P. Plesiat. 2007. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob. Agents Chemother. 51:1582-1583.
11. Jacoby, G. A. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
12. Juan, C., B. Moya, J. L. Perez, and A. Oliver. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level β-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.
13. Kresken, M., J. Brauers, and B. Korber-Irrgang. 2007. In vitro activities of ceftobiprole (BPR) combined with amikacin (AMK) or levofloxacin (LVX) against Pseudomonas aeruginosa (PA) by time kill methodology, poster E-273. 47th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
14. Laohavaleeson, S. L., K. Lolans, J. P. Quinn, J. L. Kuti, and D. P. Nicolau. 2008. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infect. Drug Resist. 1:51-55.
15. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
16. Louie, A., C. Fregeau, W. Liu, K. Bush, G. Noel, and G. L. Drusano. 2008. Ceftobiprole and levofloxacin are synergistic against an isolate of Pseudomonas aeruginosa as evaluated in a neutropenic mouse thigh infection model, poster O144. ECCMID 18th Eur. Congr. Clin. Microbiol. Infect. Dis., Barcelona, Spain.
17. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
18. Matthew, M., and A. M. Harris. 1976. Identification of β-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. J. Gen. Microb. 94:55-67.
19. Mesaros, N., Y. Glupczynski, L. Avrain, N. E. Caceres, P. M. Tulkens, and F. Van Bambeke. 2007. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 59:378-386.
20. Moya, B., A. Dotsch, C. Juan, J. Blazquez, L. Zamorano, S. Haussler, and A. Oliver. 2009. β-Lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 5:e1000353.
21. Muller, P. Y., H. Janovjak, A. R. Miserez, and Z. Dobbie. 2002. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372-1374.
22. Nicholson, S. C., R. S. Strauss, B. Michiels, and G. J. Noel. 2008. Efficacy of ceftobiprole compared to ceftriaxone linezolid for the treatment of subjects hospitalized with community-acquired pneumonia, poster C-16. Int. Conf. Am. Thorac. Soc., Toronto, Ontario, Canada.
23. Noel, G. J., K. Bush, P. Bagchi, J. Ianus, and R. S. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
24. Noel, G. L., R. S. Strauss, A. Shah, P. Bagchi, and BAP00248/307 Study Group. 2008. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia, poster K-486. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
25. Piddock, L. J. V. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402.
26. Pillar, C. M., M. K. Aranza, D. Shah, and D. F. Sahm. 2008. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J. Antimicrob. Chemother. 61:595-602.
27. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
28. Queenan, A. M., W. Shang, M. Kania, M. G. P. Page, and K. Bush. 2007. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51:3089-3095.
29. Sobel, M. L., G. A. McKay, and K. Poole. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47:3202-3207.
30. Tam, V. H., K.-T. Chang, A. N. Schilling, M. T. LaRocco, L. O. Genty, and K. W. Garey. 2009. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn. Microb. Infect. Dis. 63:279-285.
31. Westbrock-Wadman, S., D. R. Sherman, M. J. Hickey, S. N. Coulter, Y. Q. Zhu, P. Warrener, L. Y. Nguyen, R. M. Shawar, K. R. Folger, and C. K. Stover. 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob. Agents Chemother. 43:2975-2983.
32. Wolter, D. J., Smith-Moland, E., Goering, R. V., Hanson, N. D., and P. D. Lister. 2004. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn. Microbiol. Infect. Dis. 50:43-50.